CYCheng Yang

Cheng Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Cheng Yang has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • C. Z. Kong

    Urology Department, The First Affiliated Hospital of China Medical University, Shenyang, People’s Republic of China

    1 shared publication
  • Hongdan Li

    Key Laboratory of Molecular Cell Biology and New Drug Development of the Education, Department of Liaoning Province, Scientific Research Center of Jinzhou Medical University, Jinzhou, China

    1 shared publication
  • Liang Zhao

    School of Pharmacy, Jinzhou Medical University, Jinzhou, P R China

    1 shared publication
  • Y. X. Zhang

    Ultrasonography Department, The First Affiliated Hospital of China Medical University, Shenyang, People’s Republic of China

    1 shared publication
  • Y. Y. Zhu

    Urology Department, The First Affiliated Hospital of China Medical University, Shenyang, People’s Republic of China

    1 shared publication
  • Yijie Shi

    School of Pharmacy, Jinzhou Medical University, Jinzhou 121000, China; Liaoning Provincial Key Laboratory of Neurodegenerative Diseases, Jinzhou Medical University, Jinzhou, China

    1 shared publication

Latest Publications

  • Open Access

    Exosomes derived from siRNA against GRP78 modified bone-marrow-derived mesenchymal stem cells suppress Sorafenib resistance in hepatocellular carcinoma

    by Hongdan Li, Cheng Yang, Yijie Shi, Liang Zhao

    Sorafenib is an effective clinical drug in therapy of hepatocellular carcinoma, having led to improved prognosis in hepatocellular carcinoma patients. However acquired resistance is still being encountered. So, it is urgently to develop alternative strategies to overcome drug resistance. Exosomes can be modified with a variety of molecules, thereby acting as a vehicle for the delivery of therapeutic agents. The GRP78 is overexpressed in Sorafenib resistant cancer cells compared to Sorafenib sensitive cancer cells and thus is able to act as a target for therapy of hepatocellular carcinoma. In this study, we modified BM-MSCs to express the exosomal siGRP78. And we show that siGRP78 modified exosomes combined with Sorafenib is able to target GRP78 in hepatocellular carcinoma cells and inhibit the growth and invasion of the cancer cells in vitro. Further, siGRP78 modified exosomes combined with Sorafenib also inhibit the growth and metastasis of the cancer cells in vivo. siGRP78 modified exosomes could sensitize Sorafenib resistant cancer cells to Sorafenib and reverse the drug resistance.


  • Loss of P53 facilitates invasion and metastasis of prostate cancer cells

    by Yi Wang, Y. X. Zhang, C. Z. Kong, Z. Zhang, Y. Y. Zhu

    Prostate cancer is a lethal cancer for the invasion and metastasis in its earlier period. P53 is a tumor suppressor gene which plays a critical role on safeguarding the integrity of genome. However, loss of P53 facilitates or inhibits the invasion and metastasis of tumor is still suspended. In this study, we are going to explain whether loss of P53 affect the invasion and metastasis of prostate cancer cells. To explore whether loss of P53 influences the invasion and metastasis ability of prostate cancer cells, we first compared the invasion ability of si-P53 treated cells and control cells by wound healing, transwell assay, and adhesion assay. We next tested the activity of MMP-2, MMP-9, and MMP-14 by western blot and gelatin zymography. Moreover, we employed WB and IF to identify the EMT containing E-cad, N-cad, vimentin, etc. We also examined the expression of cortactin, cytoskeleton, and paxillin by immunofluorescence, and tested the expression of ERK and JNK by WB. Finally, we applied WB to detect the expression of FAK, Src, and the phosphorylation of them to elucidate the mechanism of si-P53 influencing invasion and metastasis. According to the inhibition rate of si-P53, we choose the optimized volume of si-P53. With the volume, we compare the invasion and metastasis ability of Du145 and si-P53 treated cells. We find si-P53 promotes the invasion and metastasis in prostate cancer cells, increases the expression and activity of MMP-2/9 and MMP-14. Also, si-P53 promotes EMT and cytoskeleton rearrangement. Further analyses explain that this effect is associated with FAK-Src signaling pathway. Loss of P53 promotes the invasion and metastasis ability of prostate cancer cells and the mechanism is correlated with FAK-Src signaling pathway. P53 is involved in the context of invasion and metastasis.